SCHEMBL4850255

SCHEMBL4850255

COc1cccc(CC(CN)Nc2nnc(-c3ccc4cnccc4c3)s2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK1 Q13464 5/20 0.49
PRKACA P17612 4/20 0.49
SGK1 O00141 1/20 0.46
CDK2 P24941 1/20 0.46
AKT1 P31749 1/20 0.46
DYRK1A Q13627 1/20 0.43
ROCK2 O75116 3/20 0.42
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
KDM4E B2RXH2 3/20 0.39
HSD17B10 Q99714 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
USP2 O75604 1/20 0.39
ALDH1A1 P00352 1/20 0.39
HPGD P15428 1/20 0.39
ESR1 P03372 1/20 0.38
POLB P06746 1/20 0.38
RXFP1 Q9HBX9 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4796693 0.92 ROCK1 (0.50) ROCK1PRKACASGK1CDK2AKT1
SCHEMBL4779177 0.90 KDM4E (0.44) ROCK1PRKACASGK1CDK2AKT1
SCHEMBL4899252 0.88 AKT1 (0.53) ROCK1SGK1CDK2AKT1ROCK2
SCHEMBL4780577 0.88 AKT1 (0.53) ROCK1SGK1CDK2AKT1ROCK2
SCHEMBL4898277 0.88 AKT1 (0.53) ROCK1SGK1CDK2AKT1ROCK2
SCHEMBL4895598 0.87 AKT1 (0.47) ROCK1PRKACASGK1CDK2AKT1
SCHEMBL4902382 0.87 AKT1 (0.50) ROCK1PRKACASGK1CDK2AKT1
SCHEMBL4898308 0.87 AKT1 (0.50) ROCK1PRKACASGK1CDK2AKT1
SCHEMBL4893264 0.85 AKT1 (0.57) SGK1CDK2AKT1KDM4EHSD17B10
SCHEMBL4894737 0.85 AKT1 (0.57) SGK1CDK2AKT1KDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080242694-A1 Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith D SIDOCKY NEIL R 2008-10-02 US disclosed
US-20080242694-A1 Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith D SIDOCKY NEIL R 2008-10-02 US disclosed
US-20080242694-A1 Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith D SIDOCKY NEIL R 2008-10-02 US disclosed
WO-2008036308-A2 AMINO-SUBSTITUTED HETEROCYCLES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH SIGNAL PHARMACEUTICALS, LLC (US) 2008-03-27 WO disclosed
WO-2008036308-A2 AMINO-SUBSTITUTED HETEROCYCLES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH SIGNAL PHARMACEUTICALS, LLC (US) 2008-03-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242694-A1 Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith JAK2, CHEK2, MTOR ROCK1 1312/4885PRKACA 209/4885SGK1 467/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.